ERBB2 and metabolic syndrome: HER2+ BC patients meeting the criteria of a MetS diagnosis also had an increased risk of all-cause and BC-specific mortality (HR = 3.45 95% CI 1.45–8.22 and HR = 5.05, 95% CI 1.80–14.20, respectively).